Table 3.

Dose Escalation Regression Estimates – Inflixim ab and Etanercept Dependent Variables (Increase in dose for Inflixim ab or Etanercept 1 = yes, 0 = no)

Parameter	Level	Estimate	Odds-Ratio	Transformed Odds Ratio	Conditional Probability	p-value
Intercept		-0.3129	0.73	n.a.	n.a.	0.1702
HMO	Yes	-0.2246	0.80	1.00	0.37	0.0826
	No	0.0000	1.00	1.25	0.42
Treatment	Inflixim ab	0.0000	1.00	6.38	0.42
	Etanercept	-1.8529	0.16	1.00	0.10	<.0001
Region	West	0.0000	1.00	1.00	0.42
	Northeast	0.6505	1.92	1.92	0.58	0.0215
	Midwest	0.6382	1.89	1.89	0.58	0.0063
	South	0.6252	1.87	1.87	0.58	0.0102
Pre-Period Non RA Related Costs ('000s)	Yes	0.0350	1.04	1.04	0.43	0.0185
	No		1.00	1.00	0.42
Crohn's Disease	Yes	-0.7328	0.48	1.00	0.26	0.0477
	No	0.0000	1.00	2.08	0.42
Cox-IIs	Yes	0.3064	1.36	1.36	0.50	0.0175
	No	0.0000	1.00	1.00	0.42